<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="267">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363099</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01059-30</org_study_id>
    <nct_id>NCT04363099</nct_id>
  </id_info>
  <brief_title>Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.</brief_title>
  <acronym>COVID AMBU 60</acronym>
  <official_title>Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maison de Sante Pluridisciplinaire de Creil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maison de Sante Pluridisciplinaire de Creil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since December 2019, a new agent, the coronavirus SARS-Cov-2, has spread from China to the
      rest of the world causing an international epidemic of respiratory diseases called COVID-19.
      Oise was one of the first clusters in France, with more than 4,000 confirmed cases. A
      significant proportion (80%) of patients with COVID-19 are ambulatory. However, few data are
      available for this particular population in France. Thus, few clear recommendations are
      available.

      We propose to conduct a large cohort of observation of suspected or confirmed COVID-19
      patients on an ambulatory basis in the Oise region. This observatory will make it possible to
      describe the epidemiological characteristics and initial management of COVID-19 patients and
      to identify early severity factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical description of covid 19 ambulatory cases.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological and radiological description of ambulatory cases</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of positive cases (PCR and/or serological positive)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>outpatients COVID 19 positive</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational</intervention_name>
    <description>observational management of outpatients COVID 19</description>
    <arm_group_label>outpatients COVID 19 positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ambulatory patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with covid 19 symptoms

          -  patients who had a contact with a person PCR Covid 19+

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Svetlane DIMI, M.D</last_name>
    <phone>+33650002085</phone>
    <email>svetlane.dimi@sfr.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Msp de Creil</name>
      <address>
        <city>Creil</city>
        <zip>60100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlane DIMI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maison de Sante Pluridisciplinaire de Creil</investigator_affiliation>
    <investigator_full_name>DIMI Svetlane</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>ambulatory</keyword>
  <keyword>outpatients</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Oise, France</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

